

# Improving Pancreatectomy Care in a State-Wide Quality Collaborative: A Brief Review

Cameron Harter\*, MSc; Michael Englesbe†, MD; Hari Nathan‡, MD; Brooke Bredbeck§, PhD, MD

**Background:** Pancreatectomies are among the most morbid operations performed in Michigan and they carry significant variation in outcomes postoperatively with regards to complication, readmission and reoperation rates as well as hospital length of stay. Here we demonstrate how findings from The Michigan Surgical Quality Collaborative (MSQC), a collaborative of Michigan Hospitals dedicated to surgical quality improvement, have constructed a pancreatectomy clinical care pathway capable of improving pancreatectomy outcomes.

**Materials & Methods:** The pancreatectomy care pathway we propose is a compilation of current pathways or guidelines currently in use at peer institutions, reviewed and edited by surgeon representatives to generate a consensus pathway categorized by phase: preoperative, immediate preoperative, intraoperative, postoperative and post-discharge. Each phase focuses on various aspects of clinical care that could be standardized across hospitals and implemented to improve quality of patient care.

**Results:** Outcomes we discuss include hospital length of stay, spending, pathway implementation and the limitation of outcome markers such as complications, morbidity and mortality. Barriers to this pathway are included as well.

**Conclusions:** By outlining our pancreatectomy pathway and its potential benefits, we aim to demonstrate the importance of implementing this pathway in hospitals across the

\*University of Michigan Medical School, University of Michigan, Ann Arbor MI, camharte@med.umich.edu

†University of Michigan Medical School, University of Michigan, Ann Arbor MI; Department of Surgery, University of Michigan, Ann Arbor MI; Center for Healthcare Outcomes and Policy, Ann Arbor MI; Michigan Surgical Quality Collaborative, Ann Arbor MI, englesbe@med.umich.edu

‡University of Michigan Medical School, University of Michigan, Ann Arbor MI; Department of Surgery, University of Michigan, Ann Arbor MI; Center for Healthcare Outcomes and Policy, Ann Arbor MI; Michigan Surgical Quality Collaborative, Ann Arbor MI, drnathan@med.umich.edu

§Department of Surgery, University of Michigan, Ann Arbor MI; Center for Healthcare Outcomes and Policy, Ann Arbor MI; Michigan Surgical Quality Collaborative, Ann Arbor MI, bbredbec@med.umich.edu (corresponding author)

doi: 10.3998/mjm.6253

Conflicts of interest:

Michael Englesbe receives salary support from Blue Cross and Blue Shield of Michigan.

state of Michigan. Using this pathway as an example, we hope to impress upon others the need to utilize care pathways in order to optimize systems of pancreatectomy care universally.

---

### Keywords

pancreatectomy • clinical care pathway • MSQC • Michigan Surgical Quality Collaborative

## Introduction

Pancreatectomies are among the most morbid operations performed in Michigan, with significant variation in outcomes status post pancreatectomy. Reliability-adjusted complication rates range from 29–42%, while readmission rates range from 11–24%, reoperation rates from 3–11%, and hospital stays can vary from 9–14 days across 28 hospitals in the state of Michigan. While previous work demonstrated superior outcomes in pancreatic resections performed at high-volume centers,<sup>1</sup> patient preference and growing expertise in complex surgery drive an increasing number of cases to be performed at community hospitals.

The Michigan Surgical Quality Collaborative (MSQC) aims to improve care at all participating institutions to meet the needs of Michigan residents through the adoption of a collaborative care pathway. While it is uncertain whether travel distance plays a major role in hospital selection for high-risk surgical cases, it nevertheless remains a factor in choosing a location for surgery. In turn, this makes frequent referrals to large cancer centers for care an untenable proposition for many members of our statewide surgeon community.<sup>2</sup> Improving and standardizing care for operations like a pancreatectomy will have a positive spill-over impact on many systems of care within community hospitals. To optimize systems of care at all hospitals and among all surgeons in Michigan who perform pancreatectomies, our proposed strategy involves the development and implementation of a statewide pancreatectomy care pathway informed by quality evidence and high-performing surgeons.

Clinical care pathways are standardized tools for routine operations that improve patient outcomes after surgery. Led by high-performing sites and the best evidence, teams of surgeons from across the state come together to draft a statewide care pathway. Existing pathways include colectomy, lap cholecystectomy, hernia repair, and hysterectomies. Once complete, surgeons return to their institution to discuss the pathway in detail with partners and colleagues. All sites have the option to edit the pathway to fit their institution's unique needs, but within a single site, there should be a single common pathway for care.

## Pancreatectomy Clinical Care Pathway Development

In an effort to design a pancreatectomy pathway that would be broadly implemented at all MSQC hospitals, we solicited current pathways or guidelines in use at peer institutions. Recommendations organized by phase (pre-, peri- and postoperative) were assembled into a document for presentation. Participating hospitals sent surgeon representatives to review and edit the document until a consensus pathway was finalized. The pathway was sent for approval to the executive committee of the MSQC. After approval, each surgeon representative presented the pathway to their respective institution. Institution-specific additions or changes (e.g. surgical technique) that do not fundamentally alter the MSQC-approved pathway may be made at that time.

## Components of the pancreatectomy pathway

Our pancreatectomy pathway is categorized by phase: preoperative, immediate preoperative, intraoperative, postoperative, and post-discharge (Figure 1). In the preoperative phase, special consideration is given to patient education, imaging considerations, prehabilitation, and tumor board discussion. Multimodal analgesia to reduce opioid use, infection prevention measures, and venous thromboembolism (VTE) prophylaxis are the intraoperative focus. Components of the postoperative phase include initiating proton pump inhibitor therapy, early foley removal, early alimentation, and discontinuation of IV antibiotics. Operative report standards were set to include pancreatic duct size, texture, vascular reconstruction, presence of a stent, and the type of neoadjuvant treatment utilized. Ultimately, patients meet discharge criteria if they are tolerating a diet without nausea and pain is well-controlled with oral medications. Post-discharge, patients are contacted within two business days and have a clinic visit within 2–6 weeks.

## Potential benefits of a statewide pancreatectomy care pathway

### *Hospital Length of Stay & Reduced Spending*

Hospital length of stay (HLOS) varies greatly between MSQC hospitals, and literature within NSQIP supports this finding.<sup>3</sup> Research performed at the single institution level suggests that the implementation of a care pathway lowers HLOS, particularly for institutions that already have higher HLOS at baseline.<sup>1,4,5</sup> Given this variability within HLOS, we expect HLOS to decrease most in outlier institutions, lowering variability and ensuring standardized quality care across participating MSQC institutions. In parallel, the implementation of a care pathway may reduce total hospital spending.<sup>5</sup> One institution found that a decrease in HLOS was associated with a significant decrease in inpatient spending.<sup>4</sup> With accelerating healthcare costs noted across the country,<sup>6</sup> any decrease in spending is welcome.

### *Low burden of implementation*

In conjunction with reduced spending, the implementation of a care pathway is enticing because it is resource-friendly and easily implemented across institutions. Few resource requirements are needed in order to translate a pathway into practice. Kennedy et al. showed that they were able to implement an outside institution's pancreatectomy pathway without substantial resources.<sup>7</sup> Overall, a pancreatectomy care pathway would be cost-effective, and it would ensure quality care with minimal requirements from staff or hospitals, thereby allowing a variety of institutions to adopt this pathway with ease.

### *Complications, Morbidity, and Mortality*

Studies have demonstrated that another benefit of implementing an organized care pathway at the individual institution level is that it improves quality indicators such as glycemic control, incentive spirometer usage, and time to recovery and discharge with fewer postoperative complications.<sup>4</sup> Single institution studies have not found morbidity or mortality improvements pre- versus post-pancreatectomy pathway implementation. However, this has not been studied on a multi-institutional level, which in turn limits the ability to assess care pathway quality markers such as morbidity and mortality.<sup>4</sup>

## Whipple Care Pathway

## PREOPERATIVE

<b>Patient Education/Prehabilitation</b> <ul style="list-style-type: none"> <li>-Do not delay surgery &gt; 4 weeks</li> <li>-Surgery goal/expectation setting</li> <li>-Tobacco cessation</li> <li>-Nutrition assessment and counseling</li> <li>-Functional status and exercise guidance</li> <li>-Cardiopulmonary testing<sup>14</sup> as indicated</li> <li>-Social work evaluation/screening if available</li> <li>-Education: home medications, incentive spirometer, pain management</li> <li>-Consider weight loss counseling for BMI &gt; 35 in elective non-cancer cases.<sup>1</sup></li> <li>-Prehabilitation program when available</li> </ul>	<b>Preoperative Planning</b> <ul style="list-style-type: none"> <li>-Anticipate discharge needs/care coordination</li> <li>-Consult for patients on anti-coagulation to establish plan for peri-op anticoagulation<sup>14</sup></li> <li>-Schedule post-hospital visit. For cancer patients, coordinate with oncology<sup>14</sup></li> <li>-Imaging: CT with contrast or MRI with contrast within 60 days before surgery</li> <li>-Tumor board/multidisciplinary discussion for cancer patients</li> </ul>	<b>Labs</b> <ul style="list-style-type: none"> <li>-COMP</li> <li>-Pre-albumin</li> <li>-CBC with differential</li> <li>-INR</li> <li>-PTT</li> <li>-Type and Screen</li> <li>-HbA1c for all patients</li> <li>-Tumor markers as appropriate</li> </ul>	<b>Glycemic Control</b> <ul style="list-style-type: none"> <li>-If HbA1C <math>\geq</math> 6.5%: Consult to endocrinology or primary care for management for glycemic control</li> <li>-If HbA1C <math>\geq</math> 8% or glucose &gt;250 mg/dL: Consult to endocrinology or primary care for management for glycemic control AND consider alternative surgery date if appropriate</li> </ul>
--	---	---	--

## IMMEDIATE PREOP

<b>Shower</b> <ul style="list-style-type: none"> <li>-Shower with soap or antiseptic agent on at least the night before surgery</li> <li>-Provide product and clear instruction</li> </ul>	<b>Carbohydrate Loading</b> <ul style="list-style-type: none"> <li>-Consider carb loading in all<sup>14</sup> patients</li> <li>Examples: white grape juice, apple juice, clearfast, maltodextrin, Gatorade, Impact</li> </ul>	<b>Reduced Fasting</b> <ul style="list-style-type: none"> <li>-Clear liquids up until 2 hours prior to surgery</li> </ul>	<b>Glycemic Control</b> <ul style="list-style-type: none"> <li>-Check baseline glucose level on all patients in pre-op if not done in preop appointment</li> </ul>
--	--	---	--

<b>Prevention of PONV</b> <ul style="list-style-type: none"> <li>-Screen all patients for PONV risk</li> <li>-Administer antiemetic regimen based risk assessment score: Dexamethasone 4-8mg IV after induction, Ondansetron 4mg IV at end of surgery; diphenhydramine</li> <li>-Risk Assessment Example:           <ul style="list-style-type: none"> <li>4 Primary Risk Factors: Female; Non-smoker; History or motion sickness; previous PONV; Expected administration of postoperative opioids.</li> </ul> </li> <li>Score 1 for each applicable risk factor</li> <li>0-1 risk factors: Ondansetron 4mg 15min prior to end of case</li> <li>2 risk factors: Choose one or two agents listed below</li> <li>3 risk factors: Choose one or two agents listed below</li> <li>4 risk factors: Apply Scopolamine patch at least 2 hours before induction, Administer</li> </ul>	<b>Multimodal Analgesia</b> <ul style="list-style-type: none"> <li>-Administer <math>\geq</math> 2 non-opioid analgesia strategies</li> <li>Examples:           <ul style="list-style-type: none"> <li>-epidural for those at risk for narcotic dependency<sup>14</sup></li> <li>-Regional (TAP/QL block)</li> <li>-Acetaminophen</li> <li>-Gabapentin</li> <li>-Celebrex</li> </ul> </li> <li>-Review pain management plan before anesthesia induction</li> </ul>	<b>Appropriate IV Prophylactic Antibiotics</b> <ul style="list-style-type: none"> <li>-Administer 15 to 60 minutes before incision</li> <li>-MSQC Recommendation:           <ul style="list-style-type: none"> <li>Cefazolin 2 g IV; 3 g if <math>\geq</math> 120 kg + Metronidazole 500 mg OR Cefoxitin 2 g</li> <li>OR Ceftriaxone/Flagyl or Cipro/Flagyl</li> </ul> </li> <li>-PCN allergy: Conduct thorough review of reported reaction to evaluate if alternative regimen necessary. Consider allergy testing to confirm.</li> <li>-See ASHP guidelines in MSQC resources for other acceptable antibiotic regimens and beta-lactam alternatives</li> </ul>
--	--	---

## INTRAOP

<b>VTE Prophylaxis</b> <ul style="list-style-type: none"> <li>-Within 2 hours before surgery:           <ul style="list-style-type: none"> <li>-Heparin 5000 units OR Lovenox 40</li> </ul> </li> <li>-Place SCD's</li> </ul>	<b>Alcohol-based Skin Preparation</b> <ul style="list-style-type: none"> <li>-Use alcohol-based prep unless contraindicated</li> </ul>	<b>Normothermia</b> <ul style="list-style-type: none"> <li>-Maintain core body temperature of 96.8°F (36°C)</li> <li>-Apply forced air warming</li> <li>-Consider use of fluid warmer if duration of surgery is &gt;4 hours, or expected blood loss is &gt;500 ml, or expected fluid infusion is &gt;3 liters<sup>14</sup></li> </ul>	<b>Lung Protective Ventilation</b> <ul style="list-style-type: none"> <li>-For patients with normal pulmonary function undergoing general anesthesia with endotracheal intubation, administer increased P/FiO<sub>2</sub> during surgery and after extubation in the immediate postoperative period.</li> <li>-To optimize tissue oxygen delivery, maintain perioperative normothermia and adequate volume replacement</li> </ul>	<b>Glycemic Control</b> <ul style="list-style-type: none"> <li>-DM: Check glucose every 1-2 hours</li> <li>-NDM: Consider at discretion of preop glucose/HbA1c</li> <li>-Goal &lt;180 mg/dL</li> <li>-Treat with subcutaneous rapid acting insulin or IV insulin infusion</li> </ul>
---	--	---	---	--

<b>Euvolemia</b> <ul style="list-style-type: none"> <li>-Avoid excess fluid administration. Discuss restrictive fluid strategy/goal-directed fluid therapy with anesthesia (&lt; 10 ml/kg/hr) 2</li> <li>-Use balanced chloride-restricted crystalloid solution</li> <li>-Minimize blood transfusion. Intraoperative transfusion only after discussion between anesthetic and surgical staff. If agreed, and unless there is major hemorrhage, transfuse 1 unit and assess. Target hemoglobin &gt; 7 g/dL1</li> </ul>	<b>Multimodal Analgesia</b> <ul style="list-style-type: none"> <li>-Administer <math>\geq</math> 2 non-opioid analgesia strategies</li> <li>Examples:           <ul style="list-style-type: none"> <li>-IV Lidocaine</li> <li>-Wound infiltration with long-acting anesthetic at surgical site</li> <li>-IV Opioid (acetaminophen) if not given preop</li> <li>-Regional (TAP/QL block) if not done preop</li> <li>-Ketamine</li> <li>-Ketorolac at end of case</li> </ul> </li> </ul>	<b>Redosing of Antibiotics</b> <ul style="list-style-type: none"> <li>-Cefazolin: 4 hour interval</li> <li>-Metronidazole: If operative time &gt;8 hours consider redosing</li> </ul>	<b>Drains</b> <ul style="list-style-type: none"> <li>-Foley</li> <li>-For PJ (pancreaticojejunostomy), pull NG by POD 1</li> </ul>
---	--	---	--

## POSTOP

<b>Normothermia in PACU</b>  -Maintain temperature >96.8°F (36°C) in PACU -Utilize forced air warmer PRN	<b>Labs</b>  -COMP -CBC	<b>Incentive Spirometer</b>  -Use 10x/hour while awake -Wean supplemental O2 to SPO2 > 92%	<b>Minimize IV Fluids</b>  -Minimize and discontinue fluids early as possible	<b>Early Ambulation</b>  -Ambulation starting on POD 1 -ambulate at least 3 times a day -HOB at 30 degrees at all times	<b>Early Foley Removal</b>  -Remove Foley on or before POD 2 in all patients without voiding difficulty -Bladder scan if not voiding spontaneously p 6 hours. Straight cath x 2 for urinary retention > reinsert Foley and follow-up with Urology for male patients <sup>14</sup>	<b>Early Alimentation<sup>14</sup></b>  -Gum chewing POD 0 -Ice chips/sips < 8oz in 8hrs -Goal: Regular diet by POD 3
<b>Multimodal Analgesia</b>  -Use narcotic analgesics only if needed -Administer ≥ 2 non-opioid analgesia strategies  <i>Examples:</i> -Acetaminophen -Gabapentin -Ketorolac -Ibuprofen -IV Lidocaine	<b>Glycemic Control</b>  -Goal: <180 mg/dL <b>NDM patients with normoglycemia before or during surgery:</b> -Check glucose on morning of POD1 before meal to monitor for stress-induced hyperglycemia <b>NDM patients with elevated glucose before or during surgery:</b> -Check glucose for 24-48 hours until at or below target goal -If elevated, IV insulin while NPO and basal-bolus insulin regimen once resuming oral nutrition. Consult endocrinology or medicine for diabetic management. <b>DM patients:</b> -Standard glucose monitoring, Q6h -IV insulin while NPO and basal-bolus insulin regimen once oral nutrition resumed. Consult endocrinology or medicine for diabetic management.			<b>Medications</b>  -Perioperative PPI scheduled -Diuretics as indicated -Home meds- Resume when indicated -Consider pancreatic enzymes supplements when indicated	<b>VTE Prophylaxis</b>  -Heparin 5000 units subcutaneous TID or Lovenox 40 QD -Lovenox for 28 days for cancer patients -SCDs while in bed	
<b>Discontinue Prophylactic IV Antibiotics</b>  -Prophylaxis is typically not warranted past surgery end time (possible exception – biliary stents). -If continued, duration should be no more than 24 hours past surgery end time unless otherwise indicated.	<b>Op Report Dictation:</b>  Be sure to document: -Pancreatic duct size in mm -Pancreas texture - hard/soft -Vascular reconstruction- venous/arterial/both -Presence of stent -Neoadjuvant treatment			<b>Patient Education</b>  -Diet, dehydration -Discharge planning -Encourage clinic contact vs. ED presentation- provide with clinic phone number	<b>Discharge Criteria</b>  (1) Tolerating diet without nausea or has nutritional plan (2) Pain controlled with oral meds only	

## POST-DISCHARGE

<b>Contact Patient within 2 business days</b> <ul style="list-style-type: none"> <li>-Make postop phone call to patients within 2 days of discharge</li> </ul>	<b>Clinic Visit within 2-6 weeks</b> <ul style="list-style-type: none"> <li>-Clinic visit within 2-6 weeks of discharge, consider earlier visit</li> <li>-Oncology within 12 weeks when indicated</li> <li>-Utilize telemedicine or postop clinic for early follow up visit</li> </ul>
--	--

Figure 1. Pancreatectomy Care Pathway

## Barriers to Clinical Care Pathway Implementation

Despite an overall positive perception of clinical care pathways, barriers to their implementation exist at the cultural, educational, and patient levels.<sup>8</sup> In a single institution qualitative study, a commonly cited barrier to implementation was the dichotomy between the new pathway and current provider practice patterns. Provider experience and familiarity with particular clinical practices represent a cultural barrier to implementation. Additionally, poor awareness of the pathway and frequent provider turnover limits adherence to pathways at the educational level. Finally, each patient's unique clinical presentation and individual hospital course can impact one's ability to adhere to clinical care pathways.

## Conclusion

In spite of the barriers that challenge the uptake of clinical care pathways, implementation of a statewide pancreatectomy care pathway will improve standardization of care for such procedures. As complex procedures like pancreatectomies continue to branch out into surrounding community hospitals, surgeons across the state are eager to collaborate to improve the quality of care by working together to make a standard pathway. Our care pathway, unique in its reach across the state of Michigan, exemplifies an evidenced-based and practical treatment plan supported by evidence and high-performing expertise in perioperative pancreatectomy care.

In the future, within our collaborative, we plan to analyze complication rates and better understand how morbidity and mortality are impacted across MSQC institutions after this standardized pancreatectomy care pathway is implemented. Guided by these data, surgeon leaders will engage in an iterative process following a continuous quality improvement framework to optimize complex surgical care for patients across the state of Michigan.

## Acknowledgements

This work was supported by the National Institutes of Health T32 Ruth L. Kirschstein National Research Service Award as well as Blue Cross and Blue Shield of the Michigan value partnership program.

## References

1. **La Torre M, Nigri G, Ferrari L, Cosenza G, Ravaioli M, Ramacciato G.** Hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. *The American Journal of Surgery*. 2012;78(2).
2. **Yahanda AT, Lafaro KJ, Spolverato G, Pawlik TM.** A Systematic Review of the Factors that Patients Use to Choose their Surgeon. *World J Surg*. 2016;40(1):45–55.
3. **Nussbaum DP, Penne K, Speicher PJ, Stinnett SS, Perez A, White RR, et al.** The role of clinical care pathways: an experience with distal pancreatectomy. *Journal of Surgical Research*. 2014;190(1).
4. **Denbo JW, Bruno M, Dewhurst W, Kim M, Tzeng C-W, Aloia T, et al.** Risk-stratified clinical pathways decrease the duration of hospitalization and costs of perioperative care after pancreatectomy. *Surgery*. 2018;164(3).

5. **Joliat G, Labgaa I, Petermann D, Hubner M, Griesser A, Demartines N**, et al. Cost-benefit analysis of an enhanced recovery protocol for pancreaticoduodenectomy. *British Journal of Surgery*. 2015;102(13).
6. **CMS.gov**. Historical. <https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthexpenddata/nationalhealthaccountshistorical>. Accessed 29 Dec. 2022.
7. **Kennedy EP, Rosato EL, Sauter PK, Rosenberg LM, Doria C, Marino IR**, et al. Initiation of a critical pathway for pancreaticoduodenectomy at an academic institution—the first step in multi-disciplinary team building. *Journal of the American College of Surgeons*. 2007;204(5).
8. **Madsen HJ, Lambert-Kerzner A, Mucharsky E**, et al. Barriers and Facilitators in Implementation of an Esophagectomy Care Pathway: a Qualitative Analysis. *J Gastrointest Surg*. 2022.
9. **Whipple Care Pathway Michigan Surgical Quality Collaborative**. MSQC Quality Improvement. <https://msqc.org/quality-improvement/msqc-care-pathways/>.